Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 3/20 | 0.33 |
| ▸ | RARG | P13631 | 3/20 | 0.33 |
| ▸ | RXRA | P19793 | 3/20 | 0.33 |
| ▸ | RARA | P10276 | 2/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | HNF4A | P41235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL671059 | 0.79 | SSTR5 (0.36) | RARBRARGRXRARARAPTGS1 | |
| SCHEMBL13423098 | 0.77 | GABRA1 (0.39) | RXRAPTGS1PTGS2HNF4A | |
| SCHEMBL25187381 | 0.77 | ALDH1A1 (0.40) | RARBRARGRARA | |
| SCHEMBL30287150 | 0.77 | ALDH1A1 (0.40) | RARBRARGRARA | |
| SCHEMBL2599712 | 0.75 | PTGS2 (0.36) | RARBRARGRARAPTGS1PTGS2 | |
| SCHEMBL13423104 | 0.75 | RXRA (0.48) | RARBRARGRXRARARARXRB | |
| SCHEMBL289444 | 0.71 | RARB (0.55) | RARBRARGRXRARARAHNF4A | |
| SCHEMBL9053811 | 0.68 | RARB (0.46) | RARBRARGRXRARARAHNF4A | |
| SCHEMBL16259587 | 0.66 | PTGS1 (0.32) | RXRARXRBPTGS1PTGS2HNF4A | |
| SCHEMBL18211734 | 0.66 | PTGS1 (0.41) | RARBRARGRXRARARARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2605658-B1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2605658-B1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| US-8742110-B2 | Spiroxazolidinone compounds | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742110-B2 | Spiroxazolidinone compounds | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742110-B2 | Spiroxazolidinone compounds | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2605658-A1 | SPIROXAZOLIDINONE COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2012024183-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012024183-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | SSTR5, SSTR2, SSTR4 | RARB 2563/4885RARG 3101/4885RXRA 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.